- Home
- ABVX vs CFR Comparison
ABVX vs CFR Comparison
Compare ABVX & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ABVX | CFR |
|---|---|---|
| Founded | 2013 | 1868 |
| Country | France | United States |
| Employees | 69 | 6008 |
| Industry | | Major Banks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABVX | CFR |
|---|---|---|
| Price | $99.74 | $140.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | $131.31 | ★ $142.31 |
| AVG Volume (30 Days) | ★ 2.0M | 446.8K |
| Earning Date | 03-23-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $52.14 | $9.72 |
| Revenue Next Year | $4,132.27 | $4.70 |
| P/E Ratio | ★ N/A | $14.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $119.00 |
| 52 Week High | $148.83 | $148.97 |
Technical Indicators
Market Signals| Indicator | ABVX | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 56.29 |
| Support Level | $83.85 | $133.95 |
| Resistance Level | $131.50 | $140.82 |
| Average True Range (ATR) | 7.78 | 2.42 |
| MACD | -3.17 | 0.24 |
| Stochastic Oscillator | 45.16 | 88.93 |
Price Performance
Historical ComparisonAbout ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $52 billion in assets (as of March 2026), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based banking approach that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through targeted branch openings rather than acquisitions. The bank's sweet spot is small to medium-sized Texas-based commercial clients.